Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Oncology

ONCOLOGY

EXPERT-BACKED ASSAYS TO PROPEL THERAPEUTIC DEVELOPMENT

Offering more than 150 oncology-specific tests in nine subspecialty areas, Mayo Clinic Laboratories’ cancer tests are developed by an experienced team of board-certified geneticists, genetic counselors, and physicians. Each assay is validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians, whose clinical expertise enables test options that improve patient care and increase efficiency.

Mayo Clinic Laboratories innovates at the speed of medical advancement and offers full-spectrum testing across the oncological arena. From broad, next-generation sequencing (NGS) panels like MayoComplete, which examines more than 500 genes for variations associated with solid tumors; to advanced fluorescence in situ hybridization (FISH) testing for monitoring chronic lymphocytic leukemia; to polymerase chain reaction (PCR) for single gene evaluation; our molecular and cytogenetic assays span the oncological spectrum, providing insights on common and rare disease to advance clinical trials and therapeutic development.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Full suite of oncology testing Full suite of oncology testing
Full suite of oncology testing

Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.

Hereditary oncology Hereditary oncology
Hereditary oncology

Our germline test menu includes comprehensive and targeted panels as well as single gene testing. Developed in collaboration with geneticists and genetic counselors, our evaluations examine genes known for their association with cancer risk.

MayoComplete MayoComplete
MayoComplete

Including comprehensive and disease-specific panels, MayoComplete next-generation sequencing ensures each patient receives the right test and personalized answers to guide their cancer journey. Our comprehensive panel is among the largest currently available and only includes carefully vetted, actionable genes.

Comprehensive disease testing

In addition to accessing our clinically available tests, BioPharma Diagnostics partners can access oncological testing for clinical trials and be among the first to use up-and-coming tests currently in development.

  • Disease-specific NGS panels for somatic tumors, including panels specific to neuro-oncology, sarcoma, lung, colorectal, gastrointestinal stromal cancers, and more
  • MayoComplete Solid Tumor Panel, which uses NGS to evaluate 514 genes
  • Hereditary oncology NGS panels for germline assessment
  • 50+ single gene assays using FISH and PCR
  • Single gene cell-free DNA testing
  • Immunohistochemistry
  • Chromosomal microarray
  • Methylation analysis for MGMT
News and updates

The latest

Thermo Fisher Scientific: Illuminating rare cancer prognosis and improving patients’ lives

Aiming to advance understanding of hard-to-predict gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Thermo Fisher Scientific joined forces with Mayo Clinic and BioPharma Diagnostics to validate and gain U.S. regulatory clearance of a novel, automated assay aimed at detecting a biomarker associated with the progressive disease.

Learn more
Neuro-oncology: An integrated approach to interpreting genetic information from brain tumor samples 

As part of Mayo Clinic’s Neuro-Oncology practice, the Division of Laboratory Genetics and Genomics tests about 50 brain tumors a week, and upwards of 1,500 brain tumors a year from all over the world.

MayoComplete next-generation sequencing: Transforming comprehensive cancer care

Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.

Liquid biopsy offers noninvasive DNA testing for cancer care

Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.

Legislation, leadership, and MayoComplete: Dr. Bill Morice

William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Pritt and Dr. Morice discuss their new roles at Mayo Clinic and update listeners on the latest legislative news impacting the laboratory and diagnostic industries. They also highlight the launch of MayoComplete, Mayo Clinic Laboratories’ robust suite of oncology and hematology testing that uses next-generation sequencing to identify and evaluate presence of mutations.

Comprehensive panel boosts GIST diagnosis sensitivity

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

MayoComplete Next-Generation Sequencing: Oncology Subpanels

In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.

Melanoma panel provides more tumor information

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Colorectal panel provides detailed cancer information

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Focused lung panel informs the use of targeted cancer therapies

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

PIK3CA assay guides treatment of progressing breast cancer

Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.

Against the odds: Alex Kraatz

As a two-time brain tumor survivor, Alex Kraatz has been through more harrowing medical experiences in his 34 years than most people face in a lifetime. But Alex’s fighting spirit, coupled with precision laboratory testing and cutting-edge treatments, have propelled him forward, keeping him hopeful despite the odds.

The Living Breast Biobank

This unique Mayo Clinic resource offers a novel portal into the study of gene mutations before they cause breast cancer.

View More
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.